Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment.
Albrecht J, Adamson AS, Barbieri JS, Bennett DD, Kiracofe EA, Kourosh AS, Leslie KS, Merola JF, Nguyen J, Siegfried E, Strickland N, Olbricht S, Asgari MM; American Academy of Dermatology Association Task Force on Drug Pricing and Transparency.
Albrecht J, et al. Among authors: adamson as.
J Am Acad Dermatol. 2019 Feb;80(2):577-578. doi: 10.1016/j.jaad.2018.09.016. Epub 2018 Sep 20.
J Am Acad Dermatol. 2019.
PMID: 30244066
Review.
No abstract available.